Search

Roche Holding AG

Uždarymo kaina

SektoriusSveikatos priežiūra

283.2 -0.07

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

279.6

Max

286

Pagrindiniai rodikliai

By Trading Economics

Pajamos

1.7B

3.7B

Pardavimai

-15B

16B

P/E

Sektoriaus vid.

25.123

37.461

Dividendų pajamingumas

3.28

Pelno marža

23.266

Darbuotojai

103,249

EBITDA

547M

6.5B

Dividendai

By Dow Jones

Dividendų pajamingumas

Sektoriaus vid.

3.28%

2.33%

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

22B

227B

Ankstesnė atidarymo kaina

283.27

Ankstesnė uždarymo kaina

283.2

Roche Holding AG Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2025-10-23 09:32; UTC

Uždarbis

Roche Raises Full-Year Earnings Outlook as U.S. Drug-Pricing Talks Continue -- Update

2025-10-23 05:54; UTC

Uždarbis

Roche Raises Full-Year Earnings Outlook

2025-10-01 08:54; UTC

Pagrindinės rinkos jėgos

Pharma Stocks in Europe Jump After White House Unveils Drug-Buying Site

2025-09-18 14:01; UTC

Įsigijimai, susijungimai, perėmimai

Roche to Buy Maker of Fatty Liver Treatment 89bio for Up to $3.5 Billion -- 2nd Update

2025-09-18 10:05; UTC

Pagrindinės rinkos jėgos
Įsigijimai, susijungimai, perėmimai

89bio Shares Soar Premarket on Takeover by Roche

2025-09-18 10:04; UTC

Įsigijimai, susijungimai, perėmimai

Roche to Buy Maker of Fatty Liver Treatment 89bio for Up to $3.5 Billion -- Update

2025-09-18 05:37; UTC

Įsigijimai, susijungimai, perėmimai

Roche to Buy 89bio for Up to $3.5 Billion

2025-10-23 09:19; UTC

Rinkos pokalbiai
Uždarbis

Roche's Sales Slow, But Drug Pipeline Could Support Long-Term Growth -- Market Talk

2025-10-23 09:11; UTC

Rinkos pokalbiai
Uždarbis

Roche Sales Miss Driven by Underperformance of Key Drugs -- Market Talk

2025-10-23 05:09; UTC

Uždarbis

Roche 3Q Sales Up 6% At CER

2025-10-23 05:07; UTC

Uždarbis

Roche 3Q Sales CHF14.92B

2025-10-23 05:07; UTC

Uždarbis

Analysts Had Seen 3Q Sales At CHF15.17B

2025-10-23 05:07; UTC

Uždarbis

Roche See Core Earnings Per Share Growth In High-Single to Low-Double-Digit Range At CER

2025-10-23 05:05; UTC

Uždarbis

Roche Expects An Increase In Group Sales In Mid-Single-Digit Range At CER

2025-10-23 05:04; UTC

Uždarbis

Roche: Group Sales Up 7% At Constant Exchange Rates In First Nine Months

2025-10-23 05:02; UTC

Uždarbis

Roche Had Seen High-Single-Digit 2025 Core Earnings Per Share Growth at CER

2025-10-23 05:02; UTC

Uždarbis

Roche Had Seen Mid-Single-Digit 2025 Sales Growth At Constant Exchange Rates

2025-10-23 05:02; UTC

Uždarbis

Roche 9-Mos CH45.9B

2025-10-23 05:01; UTC

Uždarbis

Roche Raises 2025 View

2025-10-01 20:33; UTC

Įsigijimai, susijungimai, perėmimai

Roche Begins Tender Offer for 89bio Pursuant to Previously Announced Merger Agreement

2025-10-01 09:05; UTC

Karštos akcijos

Stocks to Watch Wednesday: Nike, Lithium Americas, Arm, Occidental -- WSJ

2025-09-18 14:12; UTC

Įsigijimai, susijungimai, perėmimai

89bio Stock Soars 86%. Why Roche Is Buying the Biopharma Company for $3.5 Billion. -- Barrons.com

2025-09-18 07:37; UTC

Rinkos pokalbiai
Įsigijimai, susijungimai, perėmimai

Roche's 89bio Acquisition Gives Its Drug Pipeline Potential Blockbuster -- Market Talk

2025-09-18 05:09; UTC

Įsigijimai, susijungimai, perėmimai

89bio Says Deal Reflects Potential of Pegozafermin Drug Candidate

2025-09-18 05:06; UTC

Įsigijimai, susijungimai, perėmimai

Roche: Deal Is Expected to Close in 4Q

2025-09-18 05:06; UTC

Įsigijimai, susijungimai, perėmimai

Roche: Deal Enhanc Portfolio in Cardiovascular, Renal, Metabolic Diseases

2025-09-18 05:05; UTC

Įsigijimai, susijungimai, perėmimai

Roche: MASH Is One of Most Prevalent Comorbidities of Obesity

2025-09-18 05:05; UTC

Įsigijimai, susijungimai, perėmimai

Roche: 89bio Developing Potential Treatment for Metabolic Dysfunction-Associated Steatohepatitis

2025-09-18 05:04; UTC

Įsigijimai, susijungimai, perėmimai

Roche to Buy 89bio for $14.50 a Share in Cash, Contingent Value Right of Up to $6 a Share

2025-09-18 05:03; UTC

Įsigijimai, susijungimai, perėmimai

Roche: Total Deal Value Is Up to $3.5B

Roche Holding AG Prognozė

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę Roche Holding AG

Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and Oceania. The company offers pharmaceutical products in the therapeutic areas of anemia, blood and solid tumors, dermatology, hemophilia, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and transplantation. It is also developing products for various therapeutic areas. In addition, it offers in vitro tests for the diagnosis of various diseases, such as cancer, diabetes, Covid-19, hepatitis, human papillomavirus, and other diseases; diagnostic instruments; and digital health solutions. It has strategic discovery collaboration with Flare Therapeutics Inc. proteomic and mass spectrometry platform and expertise to discover novel small molecules aimed at transcription factor targets in oncology. Roche Holding AG was founded in 1896 and is based in Basel, Switzerland.
help-icon Live chat